We have addressed these questions in an aggressive low tumor mutational burden (TMB) preclinical tumor model SCC VII which generates CD4+ and CD8+ T cells specific for a set of 5 NeoAg following whole cell vaccination which can be engaged by a therapeutic peptide vaccine which requires both sets for its efficacy (27). This evidence concerns the gene CD4 and neoplasm.